Financing Diagnostics in the Post-COVID World: What the Data Shows to Date
The IVD industry is recalibrating as financing availability and valuations revert to pre-pandemic levels, following an unprecedented period of access to capital. Companies are having to do more with less, and the situation could get worse. Diagnostics, however, is too important an industry for investors to ignore, and an investor’s goal is spotting the right opportunities for rewards. By Craig Steger, Oded Ben-Joseph, PhD, and Carey Gallant, Outcome Capital, and Wendy Diller.
Read Article